As oral anticancer medications become a common treatment option, patient adherence to medication is essential to ensuring positive clinical outcomes. CANCER BUZZ spoke to Dr. Maryam Lustberg, MD, MPH, Associate Professor of Internal Medicine and Director, Center for Breast Cancer at the Yale Cancer Center, New Haven, CT, and Sandra Cuellar, PharmD, Clinical Associate Professor, Department of Pharmacy Practice at the University of Illinois at Chicago (UIC) College of Pharmacy, Chicago, IL. Hear as our experts examine challenges with oral anti-cancer therapies and provide methods to better support patients. This is the third episode of a four-part series.

Maryam Lustberg, MD, MPH

Director of the Center for Breast Cancer

Yale Cancer Center

New Haven, CT

Sandra Cuellar, Pharm.D., BCOP, FHOPA, FASHP

Clinical Associate Professor, Department of Pharmacy Practice

University of Illinois at Chicago (UIC) College of Pharmacy

Chicago, IL

Resources:

• Addressing Challenges in Oral Therapies for HR+, HER2- Breast Cancer
• Resource Library for HR+, HER- Breast Cancer
• Evolving Standards of Care for Advanced HER2+ Breast Cancer
• Metastatic Breast Cancer Project